Moreover, TP53-deficient MSCs have been reported as being associated with an increased expression of markers promoting tumorogenesis, immune suppression, drug resistance and metastasis in tumor microenvironment involving CCL5, TGF-β and IL-6/STAT3 [20]. This evidence concerns the gene TGFB1 and neoplasm.